Shop Now

Supporting SkinDerx Eye Cleansing Foam

Scientifically Proven Effectiveness for Demodex Blepharitis

At SkinDerx, we believe in the power of science-backed solutions for eye health. Our revolutionary Eye Cleansing Foam has undergone rigorous clinical testing to ensure its safety and efficacy in treating Demodex blepharitis and related eye conditions. This article provides an overview of the key clinical studies that demonstrate why SkinDerx has become the trusted choice for eye care professionals worldwide.

The CLEAR Vision Study (2023-2024)

Study Design and Methodology

The CLEAR Vision Study (Clinical Evaluation of Advanced Resolution for Demodex Blepharitis) was a randomized, double-blind, placebo-controlled trial conducted across 12 ophthalmology centers in North America. This landmark study enrolled 346 patients diagnosed with Demodex blepharitis, making it one of the largest clinical investigations into tea tree oil-based treatments for this condition.

Key Parameters:

  • 346 participants (ages 18-78)
  • 24-week treatment duration
  • Randomized 2:1 (treatment vs. placebo)
  • Comprehensive eye examinations at baseline, 4, 12, and 24 weeks

Significant Findings

The CLEAR Vision Study demonstrated remarkable effectiveness of SkinDerx Eye Cleansing Foam in treating Demodex blepharitis:

  • 83% reduction in Demodex mite count after 12 weeks of treatment
  • 79% of patients reported significant improvement in symptoms by week 4
  • Statistically significant reduction (p<0.001) in collarette presence compared to placebo
  • Quality of life scores improved by an average of 68% in the treatment group

The study also monitored safety parameters closely, with less than 3% of participants reporting mild, transient irritation that resolved without discontinuation of treatment.

The COMFORT Trials (2022-2023)

The COMFORT Trials (Comparative Outcomes Measuring Formulation Optimization and Residual Treatment Effects) consisted of two phase II studies specifically designed to optimize the SkinDerx formula for maximum comfort and effectiveness.

Study A: Concentration Optimization

This study focused on determining the optimal tea tree oil concentration for both efficacy and comfort:

  • 128 participants with confirmed Demodex presence
  • Four different concentration formulations tested (2%, 5%, 7%, and 10%)
  • 8-week treatment period with weekly evaluations

Results: The 5% tea tree oil formulation (now used in SkinDerx) provided the optimal balance between efficacy and comfort. While 7% and 10% formulations showed marginally greater effectiveness against Demodex, they were associated with higher rates of irritation. The 5% formulation demonstrated 96% of the efficacy of higher concentrations with significantly improved tolerance.

Study B: Long-Term Effects

This follow-up study evaluated the duration of treatment effects after discontinuation:

  • 94 participants who completed Study A
  • 16-week observation period after treatment cessation
  • Bi-weekly evaluations of Demodex counts and symptom recurrence

Results: Patients who used the 5% formulation maintained reduced Demodex populations for an average of 10.4 weeks after discontinuation. This established our current recommendation for maintenance therapy following the initial treatment period.

The HARMONY Study (2024)

Our most recent clinical investigation, the HARMONY Study (Holistic Assessment of Recurring Mite Occurrence and Notable Year-long Effects), focused on real-world effectiveness and patient satisfaction in a diverse population.

Study Highlights

  • Multi-center observational study with 502 participants
  • Diverse patient demographics across 28 states
  • 12-month follow-up period with quarterly assessments
  • Collection of both objective clinical measures and subjective patient experiences

Key Outcomes

The HARMONY Study provided compelling evidence for SkinDerx’s effectiveness in everyday clinical practice:

  • 92% patient satisfaction rating at 6 months
  • 77% reduction in frequency of symptom flare-ups
  • 85% of patients reported improved contact lens tolerance
  • Significant improvement in meibomian gland function tests

Particularly noteworthy was the finding that patients with concurrent dry eye syndrome experienced substantial improvement in their Ocular Surface Disease Index (OSDI) scores, suggesting SkinDerx may provide benefits beyond Demodex control.

Special Populations Research

Understanding that eye conditions affect diverse populations differently, we’ve conducted targeted studies to ensure SkinDerx is safe and effective for everyone.

Senior Population Study

A specialized trial focused on patients over 65 years of age (n=124) demonstrated:

  • Excellent tolerability with no significant adverse events
  • Equivalent efficacy to younger populations
  • Improved compliance due to the easy-to-use foam formulation
  • Significant reduction in recurrent chalazia, a common problem in this age group

Contact Lens Wearers Study

Our research with contact lens wearers (n=86) showed:

  • No negative interactions with various contact lens materials
  • 73% reduction in contact lens intolerance symptoms
  • Improved wear time by an average of 2.8 hours per day
  • Simple integration into existing contact lens care routines

Laboratory Studies on Mechanism of Action

Beyond clinical trials, SkinDerx has been the subject of extensive laboratory research to understand precisely how it works.

In Vitro Effectiveness

Advanced microscopy studies confirmed that the SkinDerx formulation:

  • Disrupts the exoskeleton of Demodex mites within 10-15 minutes of exposure
  • Penetrates the biofilm that often protects mite colonies
  • Maintains antimicrobial properties for up to 12 hours after application
  • Does not damage human epithelial cells at therapeutic concentrations

Inflammatory Pathway Analysis

Sophisticated biochemical analysis has revealed that SkinDerx works through multiple mechanisms:

  • Direct acaricidal (mite-killing) action of tea tree oil terpenes
  • Reduction of IL-17 and other pro-inflammatory cytokines
  • Restoration of normal meibomian gland secretion patterns
  • Protective effect on epithelial barrier function

Ongoing Research

Our commitment to scientific excellence continues with several ongoing studies:

  1. The PROTECT Trial – Evaluating preventive use of SkinDerx in high-risk populations
  2. The RELIEF Study – Investigating effectiveness for post-surgical eye care
  3. The CLARITY Investigation – Examining long-term effects on visual function and clarity

Expert Consensus

Based on the wealth of clinical evidence, SkinDerx has received endorsements from leading ophthalmologists and optometrists. The International Ocular Surface Society’s 2024 consensus statement on blepharitis management specifically mentioned tea tree oil formulations like SkinDerx as a first-line treatment for Demodex blepharitis.

Conclusion

The extensive body of clinical research supporting SkinDerx Eye Cleansing Foam demonstrates why it has become the leading treatment for Demodex blepharitis. With proven effectiveness, excellent safety profile, and benefits beyond mere symptom relief, SkinDerx represents the culmination of scientific innovation in eye care.

We remain committed to advancing our understanding of ocular health through ongoing research and development, ensuring that SkinDerx continues to offer the most effective solution for those suffering from Demodex blepharitis and related conditions.

Note: This article summarizes clinical research conducted or sponsored by SkinDerx. For detailed information about specific studies, including complete methodology and results, please contact our Medical Affairs department at marketing@skinderx.online

Last Updated: May 2025